Methylprednisolone During the Switch Between Natalizumab and Fingolimod

Multiple Sclerosis Clinical Trial

— NTZ2TTY  

Official title:

Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02769689
• Other study ID #: CHU-0259
• Secondary ID: 2015-003298-14
• Status: Recruiting
• Phase: Phase 4
• Start date: June 12, 2019
• Est. completion date: July 20, 2024

Study information

• Verified date: August 2022
• Source: University Hospital, Clermont-Ferrand
• Contact: Patrick LACARIN
• Phone: 04 73 75 11 95
• Email: placarin[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NTZ) is used in the treatment of relapsing multiple sclerosis (MS). The risk of PML increases after 18 months of treatment. When switching from NTZ to another disease modifying treatment (DMT) in these MS patients with an active disease, there is a high risk of inflammatory reactivation. Nonetheless, a washout period of several weeks is necessary before initiating a new DMT.

The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).

Description:

Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo.

Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.

A spinal and brain MRI will be performed at baseline (last NTZ perfusion, noted W0) and 16 to 18 weeks after. The last clinical follow-up will be made after 24 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 56
• Est. completion date: July 20, 2024
• Est. primary completion date: June 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Relapsing-Remitting Multiple Sclerosis (Mc Donald's 2010 criteria)

• EDSS<6.0

• At least18 natalizumab infusions

• Planned switch from natalizumab to fingolimod

• Aged between 18 and 65

• Patients must have received high dose IV methylprednisolone during the 5 previous years

Exclusion Criteria:

• Progressive MS

• Uncontrolled MS with natalizumab (existence of a relapse during the previous 12 months or existence of a gadolinium enhancing lesion on a MRI performed during the last 12 months)

• SEP de forme progressive

• Contra-indication to the use of high dose oral methylprednisolone

• Marked cognitive impairment altering protocole understanding

• Switch from natalizumab to a disease modifying treatment different from fingolimod

• Contra-indication to fingolimod use

• Existence of a disease or condition that could alter study completion

• Chronic treatment with steroids

• Acute treatment with steroids (more than 300mg during the month prior to inclusion)

• Contra-indication to gadolinium containing products injection

• Pregnancy

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Methylprednisolone
Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
• Placebo
Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
• natalizumab (NTZ)
Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
• fingolimob (FTY)
Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.

Locations

Country	Name	City	State
France	CHU Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	efficacy of high dose methylprednisolone compared to that of a placebo	To evaluate the efficacy of high dose methylprednisolone given once a month during the washout period for the switch between natalizumab and fingolimod, compared to that of a placebo, on multiple sclerosis inflammatory rebound evaluated using MRI, 16 to 18 weeks after natalizumab discontinuation and clinically at 6 months	at 6 months
Secondary	comparison of the number of new T2 or gadolinium enhanced lesions on MRI in the 2 treatment groups		at 4 months
Secondary	comparison of the number of MS relapses during the 6 months after natalizumab discontinuation, in the 2 treatment groups		at 6 months
Secondary	potential correlations between previous MS activity and the risk of relapse or inflammatory rebound on MRI after natalizumab discontinuation	To study the potential correlations between previous MS activity (annualised relapse rate during the year before natalizumab initiation) and the risk of relapse or inflammatory rebound on MRI after natalizumab discontinuation, in the whole group	at 6 months
Secondary	adverse effects of high dose oral prednisolone		at 6 months
Secondary	use of methylprednisolone once every 4 weeks during the switch between natalizumab and fingolimod in patients with MS	To perform a cost utility analysis in order to evaluate the use of methylprednisolone once every 4 weeks during the switch between natalizumab and fingolimod in patients with MS	at 6 months